Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall vioxxTalks of Vioxx problems in recent years have been evident in sales for Merck & Co., though the popular drug still reached global sales of $2.5 billion in 2003. Concern over Vioxx problems first surfaced in 2000, a year after the drug was made available in the United States. By 2001, a report in the Journal of the American Medical Association connected Vioxx problems to a possible increased risk of cardiovascular disease. A three-year study by Merck was halted and a recall issued after Vioxx problems were confirmed, with risk of heart attack and stroke present after 18 months of treatment.
Public Citizen advocacy group listed Vioxx on its list of Worst Pills, Best Pills in April 2001, warning Vioxx problems were believed more prevalent than claims made by Merck that it was safer than older drugs already on the market. Skeptical about the extent of advantages the deemed “super aspirin” could provide, Public Citizen warned Merck had not done comparative long-term, higher-dose randomized trials comparing Vioxx to older drugs, and the consumer group was worried in addition to not having important advantages over existing drugs that Vioxx problems were masked in hidden dangers since a COX-2 inhibitor affects so many different parts of the body.
When the withdrawal of Vioxx was announced September 30, 2004, the FDA said it was considering whether longer studies would be needed for COX-2 inhibitors on the market and under development, which was harshly criticized to be after the fact by many fed up with the FDA''s seemingly non aggressive stance of drugs once entering the market after federal approval. Dr. Sidney Wolfe, director of health research at Public Citizen, scolded the agency because of its failure to require these exact studies from occurring in 2000, when the initial evidence of Vioxx problems arose.
The questions about FDA effectiveness over the years have been argued and in the wake of the Vioxx recall announcement, changes at the federal agency have been underway. FDA spokesperson Crystal Rice responded to the Vioxx problems by saying agency officials “believe that our actions regarding Vioxx were appropriate and consistent with our public health mission.” Even before the Vioxx recall, worrisome Vioxx problems had resulted in numerous Vioxx-related lawsuits, as well as two seeking class action status that is only predicted to take off in numbers in months to come. Senate Finance Committee Chair Chuck Grassley (R-Iowa) responded to the Vioxx recall by saying he was concerned the FDA might have been “foot dragging” in its response to Vioxx problems.
Among numerous studies indicating potential risks related to Vioxx was a study by an FDA researcher. A Vanderbilt Medical School professor who published a study in 2002 linking Vioxx problems to an increased risk of heart disease said the “FDA dropped the ball on Vioxx,” when commenting on the FDA''s “Pattern of not being able to act quickly when products are already on the market.” The Vioxx problems, in addition to potentially resulting in an estimated $1 billion in legal costs for Merck, is also expected to change the way the FDA detects risks, especially after a drug has reached the market.
Two reports released Wednesday reveal that Merck waged a deceptive promotional campaign for its top-selling painkiller Vioxx and disguised company studies as the work of outside scientists.
JAMA Studies
<...
The third-largest drugmaker in the U.S, Merck, agreed to settle a majority of their claims involving the painkiller Vioxx for $4.85 billion.
The settlement is reportedly the larg...
An Idaho state jury has found that the painkiller Vioxx contributed to the heart attack of a postal worker. The jury awarded him and his wife a multimillion-dollar verdict.
Frede...